MedTrace Logo

Quantitative Methods for Supplementing Contrast-Enhanced Magnetic Resonance Imaging of Breast Cancer

NCT02058758 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2019-09-25

No results posted yet for this study

Summary

Contrast-enhanced magnetic resonance imaging (CE-MRI) is now established as the most accurate non-invasive imaging modality for characterizing breast cancer. CE-MRI has a very high sensitivity because the intravenous MR contrast agent highlights regions with increased vascularization and vascular permeability compared to normal breast tissues and benign lesions.

Conditions

Interventions

DEVICE

Magnetic Resonance Imaging

MRI scanning with novel acquisition, reconstruction, and/or analysis methods.

Sponsors & Collaborators

Principal Investigators

  • Patrick Bolan, PhD · University of Minnesota

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-01
Primary Completion
2019-07-01
Completion
2019-09-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02058758 on ClinicalTrials.gov